PRLog - Feb. 7, 2012 - BOSTON -- The Board of Directors of the Caring for Carcinoid Foundation is pleased to announce the appointment of Ron Hollander as its new Executive Director.
The Caring for Carcinoid Foundation (CFCF) is an international organization based in Boston. CFCF aggressively funds research in pursuit of cures and effective treatments for patients with neuroendocrine cancers. Visionary innovator Steve Jobs, co-founder and former CEO of Apple Inc., passed away from a pancreatic neuroendocrine tumor in 2011.
Over 100,000 patients are living in the US with neuroendocrine tumors and incidence rates are rising. The Caring for Carcinoid Foundation is dedicated to discovering cures for patients with neuroendocrine cancers and supporting patients, their families, friends and caregivers.
“CFCF is a very special organization,”
Hollander previously served as the President and CEO of the Massachusetts Hospital Association. More recently, he has been teaching health policy at Tufts Medical School, doing strategy consulting to multi-stakeholder coalitions and speaking and writing about health reform.
“We are delighted to have someone of Ron’s caliber and integrity to lead our Foundation” said, Anne Doyle, Chair of the CFCF Board and Chief Operating Officer of Planned Parenthood League of Massachusetts. “He brings a collaborative style and strong strategic thinking that will help us strengthen and sustain our efforts well into the future.”
“The research that CFCF is doing has direct implications for many other cancer types and for the whole field of personalized medicine as well,” said Doyle.
Neuroendocrine tumors can originate almost anywhere in the body. Neuroendocrine tumors that arise in the pancreas are called “pancreatic neuroendocrine tumors” or “islet cell tumors.” Neuroendocrine tumors originating in other areas are commonly classified as “carcinoid cancer.”
For More Information visit: www.caringforcarcinoid.org.
# # #
The mission of the Caring for Carcinoid Foundation (CFCF) is to discover cures for carcinoid cancer, pancreatic neuroendocrine cancer, and related neuroendocrine cancers. CFCF also works to eliminate the suffering of patients, families, and caregivers affected by neuroendocrine cancers.
To achieve rapid discovery of a cure, CFCF directs 100% of all individual donations to fund breakthrough scientific research of carcinoid and related neuroendocrine tumors. This is made possible by the generous support of its Board of Directors and corporate sponsors.
Since its inception, CFCF has awarded over six million dollars in research grants to leading scientists at renowned research institutions. Along with its focus on research, CFCF is committed to supporting patients, families, friends and caregivers by providing them with complete and up-to-date information.